- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Börsennews zur BERGENBIO Aktie und weiteren Hot Stocks erhalten | |||||
| 02.10. | BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting | 201 | PR Newswire | BERGEN, Norway, Oct. 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications... ► Artikel lesen | |
| 27.09. | BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress | 296 | PR Newswire | BERGEN, Norway, Sept. 27, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer... ► Artikel lesen | |
| 09.09. | BerGenBio Presents Phase II Trial Updates With Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer | 346 | PR Newswire | BERGEN, Norway, Sept. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer... ► Artikel lesen | |
| 19.08. | BergenBio reports Q2 results | - | Seeking Alpha | ||
| 19.08. | BerGenBio ASA: Results for the Second Quarter and First Half 2019 | 194 | PR Newswire | - Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy
-... ► Artikel lesen | |
| 20.06. | EuroBiotech Report-Sanofi cuts, AstraZeneca in Korea, uniQure M&A, U.K. and BerGenBio | 18 | FierceBiotech | ||
| 14.06. | BerGenBio posts updated data on trial of elderly AML patients | - | FierceBiotech | ||
| 14.06. | BerGenBio to present clinical data at EHA | - | Seeking Alpha | ||
| 14.06. | BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy | 35 | PR Newswire | OSLO, Norway, June 14, 2019 /PRNewswire/ --
Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib... ► Artikel lesen | |
| 03.06. | BerGenBio Presents New Phase II Clinical Data That Bemcentinib in Combination With Low Dose Chemotherapy Improves Efficacy and Duration of Survival in Elderly AML Patients at ASCO 2019 | 19 | PR Newswire | CHICAGO, June 3, 2019 /PRNewswire/ --
Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising... ► Artikel lesen | |
| 02.06. | BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019 | 58 | PR Newswire | CHICAGO, June 2, 2019 /PRNewswire/ --
Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical... ► Artikel lesen | |
| 16.05. | BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 | 23 | PR Newswire | BERGEN, Norway, May 15, 2019 /PRNewswire/ --
Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019Non-Small-Cell Lung Cancer... ► Artikel lesen | |
| 08.05. | BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA in Patients With Advanced NSCLC | 22 | PR Newswire | Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second... ► Artikel lesen | |
| 08.05. | BergenBio reports Q1 results | - | Seeking Alpha | ||
| 08.05. | BerGenBio ASA: Results for the First Quarter 2019 | 30 | PR Newswire | - Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia
-... ► Artikel lesen | |
| 24.04. | BerGenBio ASA: Invitation to First Quarter Presentation and Webcast | 21 | PR Newswire | BERGEN, Norway, April 24, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio's senior management... ► Artikel lesen | |
| 23.04. | BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 | 40 | PR Newswire | - Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA
- Accepted for presentation at ASCO in June 2019
OSLO, Norway, April... ► Artikel lesen | |
| 09.04. | BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference | 20 | PR Newswire | BERGEN, Norway, April 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting... ► Artikel lesen | |
| 02.04. | BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy | 29 | PR Newswire | - First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing... ► Artikel lesen | |
| 02.04. | BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance | 55 | PR Newswire | Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 6,080 | +1,67 % | Medigene-Aktie: Startet gerade die große Aufholjagd? | Bei der Medigene-Aktie tut sich aktuell charttechnisch was. Nachdem der Biotech-Titel zuletzt unter Druck stand und seit Mitte September von 6,85 Euro auf 5,785 Euro gefallen ist, zeichnet sich eine... ► Artikel lesen | |
| MORPHOSYS | 98,30 | +0,67 % | MorphoSys - War das schon alles? | Rabenschwarzer Tag für die Quiagen-Aktie, die einen katastrophalen Kurssturz verbuchen muss - und damit uns Gelegenheit gibt, bei einem anderen Wert aus dem Sektor Gesundheitswesen einen ChartCheck... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,200 | -0,45 % | DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2019 (deutsch) | Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2019
DGAP-News: Heidelberg Pharma AG / Schlagwort(e): 9-Monatszahlen
Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun... ► Artikel lesen | |
| BIOGEN | 205,00 | +1,46 % | Better Buy: Biogen vs. Gilead Sciences | ||
| PALATIN TECHNOLOGIES | 0,750 | -0,21 % | Palatin Technologies Aktienexperte warnt mit einem neuen brutalen Kursziel | ||
| BRAIN | 11,900 | -0,67 % | B.R.A.I.N.: Vorschuss-Lorbeeren? | Frankfurt am Main (www.aktiencheck.de) - B.R.A.I.N.-Aktienanalyse von der EQUI.TS GmbH: Thomas J. Schießle und Daniel Großjohann, Aktienanalysten der EQUI.TS GmbH, nehmen in einer aktuellen Aktienanalyse... ► Artikel lesen | |
| ILLUMINA | 280,00 | +2,21 % | QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests | Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making
Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)... ► Artikel lesen | |
| CLINUVEL | 21,700 | -4,15 % | XFRA ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: AU000000CUV3 | ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING AU000000CUV3 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING AU000000CUV3 ARE SUSPENDED UNTIL FURTHER NOTICE. ► Artikel lesen | |
| HEAT BIOLOGICS | 0,369 | -1,60 % | Heat Biologics Aktie schon wieder im Minus: Hauptgrund ist ein neues brutales Kursziel (Geht noch tiefer) | ||
| SANGAMO THERAPEUTICS | 7,301 | -1,95 % | Should Investors Buy or Sell Sangamo Therapeutics Right Now? | ||
| TREVENA | 0,869 | -2,64 % | TREVENA INC - 8-K, Current Report | ||
| AETERNA ZENTARIS | 0,836 | +0,66 % | Aeterna Zentaris Inc (3): Aeterna Zentaris appoints Paulini CEO, replacing Ward | ||
| REGENERON PHARMACEUTICALS | 280,45 | +2,88 % | Pfizer takes aim at a flagship franchise at Sanofi and Regeneron - and scores a few direct hits | ||
| KUROS BIOSCIENCES | 2,390 | -3,24 % | Kuros Biosciences Ltd.: Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs | Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs
Schlieren (Zurich), Switzerland, October 2, 2019... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 76,58 | +1,35 % | SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm | New York, New York--(Newsfile Corp. - October 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta" or the... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
